THE LATEST ARTICLES
NEWSLETTERS
dyslexia letters
Ian Krietzberg October 16, 2025
Dr. Coral Hoh has spent nearly a decade trying to prove that Dysolve, an A.I. platform designed to treat dyslexia, actually works. A randomized controlled trial just validated her approach.
Jason Kwon
Ian Krietzberg October 14, 2025
In the wake of OpenAI’s countersuit against Elon Musk, Sam Altman’s company has sent a flurry of subpoenas to nonprofits asking for information about their funding sources, among other things. Is this a pro forma byproduct of their legal battle with Musk—or an intimidation tactic?
Grand Coulee Dam Washington
Ian Krietzberg October 9, 2025
Ever heard of little ole Quincy, a small city on the Columbia River? Well, it’s home to a Microsoft mega-facility, a BlackRock-backed A.I. firm, and a handful of other entities that are harvesting its natural gifts—including its water supply—into a mini economic miracle.
Sam Altman
Ian Krietzberg October 7, 2025
OpenAI’s new video-generation app has only been available to the public for a week and it’s already caused a reckoning in Hollywood while raising existential questions about the future of social media. In a pair of incisive conversations, Puck’s own Julia Alexander and copyright attorney Simon Pulman consider what comes next…


IMO Math Test
Ian Krietzberg October 2, 2025
An exclusive look inside Harmonic’s new A.I. math model, Aristotle—a $100 million step toward what co-founders Tudor Achim and Vlad Tenev are hoping will become the world’s first “mathematical superintelligence.”
therapy mental health
Ian Krietzberg September 30, 2025
A newish startup hopes to leverage generative A.I. to treat millions of people with cognitive issues. But like most shiny new industry objects, the next step is gathering robust evidence to prove that the system actually works.
Sam Altman
Ian Krietzberg September 25, 2025
Sam Altman’s company, which is valued at half a trillion dollars, will earn around $13 billion in revenue this year and likely burn through $100 billion by the end of the decade. Here’s why that makes sense, at least according to Global X’s Tejas Dessai.
clinical drug trial breast cancer detection
Ian Krietzberg September 23, 2025
Investors are shoveling hundreds of millions of dollars into the quixotic promise of A.I.-assisted drug discovery, but a handful of tech companies are pursuing a parallel, potentially more impactful endeavor: leveraging artificial intelligence to speed up enormously costly, time-consuming clinical trials.


Mark Kelly
Ian Krietzberg September 18, 2025
In a candid conversation, astronaut turned senator Mark Kelly discusses his new A.I. policy road map, how the private sector can help “win” the A.I. arms race, and whether going all in on the technology is wise to begin with.
chatbot ai school aducation
Ian Krietzberg September 16, 2025
News and notes on Aloe, a buzzy new entrant in the A.I. race, which is seemingly capable of building, vetting, and using tools to more reliably answer user queries.
1 5 6 7 8 9 10